PPARG and rheumatoid arthritis: The peroxisome proliferator-activated receptor gamma (PPARγ) agonists—rosiglitazone and pioglitazone—are being evaluated in ongoing phase II clinical trials for treatment of rheumatoid arthritis and SLE, respectively.